Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma
about
Brain tumorsImaging Modalities to Assess Oxygen Status in GlioblastomaThe clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesMolecular mechanisms of hypoxia in cancer.Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5)18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft modelInterrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Imaging hypoxia to improve radiotherapy outcome.Positron emission tomography radiotracers for imaging hypoxia.Molecular imaging of tumor hypoxia with positron emission tomography.Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors.Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer." in this issue of EJNMMI.Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia.Oxygen Sensing, Hypoxia Tracing and in Vivo Imaging with Functional Metalloprobes for the Early Detection of Non-communicable Diseases.
P2860
Q24605136-66C05326-B9C7-4E80-93F8-E54C10C2A92DQ26782708-C55735B1-0FC0-4D64-B6E6-2AAFEBCE3FD2Q27025579-7F65BC85-ADFF-4FD4-B827-F9492B6FDAABQ33705108-711D07D1-03E8-4700-9F81-A317F00FBD0BQ35172917-A7316869-5265-46F1-AF4C-5E01F119D131Q36340165-E1BFD25E-A52D-43A7-9846-AC3BC7E87A4CQ37165297-6CE4479A-C33D-4076-AC5A-A515027D0739Q37236103-7E52C050-19DF-4F42-863A-AC29C97B9CADQ38059626-688841F6-1938-48F2-9427-5B0B892ADFECQ38166980-9E4A431C-3D26-49D6-8A58-08E750A66625Q38199721-0460A5A5-19B0-46F5-A3F5-A0013BB9957DQ38412352-C5A0ED29-B06D-45EE-BE5C-C9010BF96E12Q43043131-EE42B830-B5C4-42F3-8049-6C2F998D71C4Q49609232-FE48C4B6-7F5F-43CD-B812-6325EB9EC767Q51487132-BD1BF38B-4D14-4352-AAC6-32F078E4D1CDQ52661554-0D9204CE-4C80-4CC4-BD84-FD37E7FD27A0
P2860
Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biodistribution and dosimetry ...... binding in human glioblastoma
@ast
Biodistribution and dosimetry ...... binding in human glioblastoma
@en
type
label
Biodistribution and dosimetry ...... binding in human glioblastoma
@ast
Biodistribution and dosimetry ...... binding in human glioblastoma
@en
prefLabel
Biodistribution and dosimetry ...... binding in human glioblastoma
@ast
Biodistribution and dosimetry ...... binding in human glioblastoma
@en
P2093
P2860
P1476
Biodistribution and dosimetry ...... binding in human glioblastoma
@en
P2093
Alexander V Kachur
Cameron J Koch
Chaitanya Divgi
Deborah Smith
James B Stubbs
Janet S Reddin
Jason Driesbaugh
Joshua S Scheuermann
Kevin D Judy
P2860
P2888
P304
P356
10.1007/S00259-010-1517-Y
P577
2010-06-29T00:00:00Z